Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on September 22, 2011, regarding an event that occurred on September 16, 2011. The company is incorporated in Delaware and maintains its principal executive offices in Berkeley Heights, New Jersey.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial metric disclosed is the market price of the company's securities, which closed below $1.00 per share for 30 consecutive business days.
Material Changes
The material change reported is the receipt of a deficiency letter from The NASDAQ Stock Market LLC. The letter notified the company that it failed to satisfy the continued listing requirement of maintaining a minimum closing bid price of $1.00 per share (Listing Rule 5450(a)(1)).
Outlook, Risks, and Contingencies
- Compliance Period: The company has 180 calendar days, until March 14, 2012, to regain compliance.
- Compliance Requirement: To remain listed, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days.
- Delisting Risk: If compliance is not achieved by the deadline, NASDAQ will issue a delisting letter.
- Remedial Options: The company may request a hearing before a Listing Qualification Panel to stay delisting or transfer its securities to The NASDAQ Capital Market, provided it meets initial listing standards (excluding bid price), which would grant an additional 180-day compliance period.
Investor Verification Checklist
- Verify the current stock price and whether it has sustained a closing bid of $1.00 or more for ten consecutive business days.
- Confirm the company's status regarding the March 14, 2012, compliance deadline.
- Check for any subsequent filings regarding a transfer to The NASDAQ Capital Market or a hearing request.
- Review the press release dated September 22, 2011 (Exhibit 99.1) for additional management commentary not included in the 8-K text.